- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01707290
Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation (KONTINUE)
A Phase 3, Two-Arm, Rollover Study to Evaluate the Safety of Long Term Ivacaftor Treatment in Subjects 6 Years of Age and Older With Cystic Fibrosis and a Non-G551D CFTR Mutation
Study Overview
Detailed Description
Ivacaftor is the first Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) modulator to show an improvement in CFTR function and clinical benefit in participants with CF. Results from Phase 3 studies (NCT00909532 [Study 102] and NCT00909727 [Study 103]) showed that ivacaftor is effective in the treatment of participants with CF who have the G551D-CFTR mutation, as evidenced by sustained improvements in CFTR channel function (measured by reduction in sweat chloride concentration) and corresponding substantial, durable improvements in lung function, pulmonary exacerbations, respiratory symptoms, and weight gain. Ivacaftor was also well tolerated, as evidenced by the rates and reasons for premature discontinuation and results of safety assessments.
Ivacaftor (Trade Name Kalydeco; 150 mg tablets) was initially approved in the United States for the treatment of CF in participants 6 years of age and older who have a G551D mutation in the CFTR gene.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Leuven, Belgium
-
-
-
-
-
Montpellier, France
-
Paris, France
-
-
-
-
-
Belfast, United Kingdom
-
Edinburgh, United Kingdom
-
-
-
-
Alabama
-
Birmingham, Alabama, United States
-
-
California
-
Palo Alto, California, United States
-
-
Colorado
-
Denver, Colorado, United States
-
-
Connecticut
-
Hartford, Connecticut, United States
-
-
Florida
-
Tampa, Florida, United States
-
-
Georgia
-
Atlanta, Georgia, United States
-
-
Illinois
-
Chicago, Illinois, United States
-
-
Iowa
-
Iowa City, Iowa, United States
-
-
Kentucky
-
Lexington, Kentucky, United States
-
-
Maryland
-
Baltimore, Maryland, United States
-
-
Massachusetts
-
Boston, Massachusetts, United States
-
-
Michigan
-
Ann Arbor, Michigan, United States
-
Detroit, Michigan, United States
-
Grand Rapids, Michigan, United States
-
-
Minnesota
-
Minneapolis, Minnesota, United States
-
-
Missouri
-
St. Louis, Missouri, United States
-
-
Nebraska
-
Omaha, Nebraska, United States
-
-
New York
-
New York, New York, United States
-
Syracuse, New York, United States
-
Valhalla, New York, United States
-
-
North Carolina
-
Chapel Hill, North Carolina, United States
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States
-
Pittsburgh, Pennsylvania, United States
-
-
South Carolina
-
Charleston, South Carolina, United States
-
-
Tennessee
-
Nashville, Tennessee, United States
-
-
Texas
-
Dallas, Texas, United States
-
Fort Worth, Texas, United States
-
Houston, Texas, United States
-
-
Utah
-
Salt Lake City, Utah, United States
-
-
Virginia
-
Richmond, Virginia, United States
-
-
Washington
-
Seattle, Washington, United States
-
-
West Virginia
-
Morgantown, West Virginia, United States
-
-
Wisconsin
-
Madison, Wisconsin, United States
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Participants from Study 110 or Study 111 entering the ivacaftor arm must have completed the assigned study drug treatment duration in the previous study.
- Participants from Study 113 entering the ivacaftor arm must have completed all study related treatments through the Follow-up Visit and met the Study 113 responder criteria during the previous study.
- Participants entering the observational arm must have completed at least 4 weeks of study drug treatment in their previous study (Study 110 or Study 111), must have completed the previous study but do not wish to enroll in the ivacaftor arm, or must have completed the previous study but do not meet the inclusion criteria of the ivacaftor arm.
- Participants of childbearing potential entering the ivacaftor arm must not be pregnant.
- Participants entering the ivacaftor arm must be willing to comply with contraception requirements.
Exclusion Criteria (Ivacaftor Arm Only):
- History of any illness or condition that might confound the results of the study or pose an additional risk in administering ivacaftor to the Participant.
- Use of moderate or strong inhibitors or inducers of cytochrome P450 (CYP) 3A.
- Evidence of cataract or lens opacity at or before the Day 1 Visit.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ivacaftor
Participants who received Ivacaftor 150 milligram (mg) tablet and/or Placebo matched to Ivacaftor tablet orally, every 12 hours (q12h) in the previous study VX11-770-110 (Study 110; NCT01614457), VX12-770-111 (Study 111; NCT01614470) or VX12-770-113 (Study 113; NCT01685801); received Ivacaftor 150 mg tablet q12h in this VX12-770-112 (Study 112; NCT01707290) up to 104 weeks.
|
150 mg tablet, oral use, every 12 hours (q12h)
Other Names:
|
No Intervention: Observational
Participants who received Ivacaftor 150 mg tablet and/or Placebo matched to Ivacaftor tablet, orally, q12h in the previous Study 110 (NCT01614457) or Study 111 (NCT01614470), were observed (did not receive study drug) in this Study 112 (NCT01707290) for up to 2 years.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Treatment Emergent Adverse Events (TEAEs) or Serious Adverse Events (SAEs) in Ivacaftor Arm
Time Frame: Day 1 up to Week 108 (Study 112)
|
AE: any untoward medical occurrence in a participants during the study; the event does not necessarily have a causal relationship with the treatment.
This includes any newly occurring event or previous condition that has increased in severity or frequency after informed consent form is signed.
AE includes serious as well as non-serious AEs.
SAE (subset of AE): medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, In-patient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event.
TEAEs were defined as adverse events with start date or increased severity on and after the first dose of study drug through Week 108.
|
Day 1 up to Week 108 (Study 112)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) at Week 2, 12, 24, 36, 48, 60, 72, 84, 96, and 104
Time Frame: Baseline, Week 2, 12, 24, 36, 48, 60, 72, 84, 96 and 104 (Study 112)
|
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
Hankinson and Wang standards were used to calculate percent predicted FEV1 (for age, gender, and height).
The Hankinson standard was used for male participants 18 years and older and female participants 16 years and older.
The Wang standard was used for male participants aged 6 to 17 years and for female participants aged 6 to 15 years.
Baseline was defined as the most recent measurement before intake of the first dose of study drug (Ivacaftor) in Study 112.
Results were planned to be reported for Ivacaftor arm and were stratified by parent study 110, 111 and 113.
|
Baseline, Week 2, 12, 24, 36, 48, 60, 72, 84, 96 and 104 (Study 112)
|
Absolute Change From Baseline in Body Mass Index (BMI) at Week 2,12, 24, 36, 48, 60, 72, 84, 96 and 104
Time Frame: Baseline, Week 2, 12, 24, 36, 48, 60, 72, 84, 96 and 104 (Study 112)
|
BMI was defined as weight in kg divided by height in m^2.
Baseline was defined as the most recent measurement before intake of the first dose of study drug (Ivacaftor) in Study 112.
Results were planned to be reported for Ivacaftor arm and were stratified by parent study 110, 111 and 113.
|
Baseline, Week 2, 12, 24, 36, 48, 60, 72, 84, 96 and 104 (Study 112)
|
Absolute Change From Baseline in Sweat Chloride at Week 2, 24, 48 and 104
Time Frame: Baseline, Week 2, 24, 48 and 104 (Study 112)
|
Sweat samples were collected using an approved collection device.
Baseline was defined as the most recent measurement before intake of the first dose of study drug (Ivacaftor) in Study 112.
Results were planned to be reported for Ivacaftor arm and were stratified by parent study 110, 111 and 113.
|
Baseline, Week 2, 24, 48 and 104 (Study 112)
|
Absolute Change From Baseline in Respiratory Domain of the Cystic Fibrosis Questionnaire Revised (CFQ-R) at Week 2, 12, 24, 36, 48, 60, 72, 84, 96 and 104
Time Frame: Baseline, Week 2, 12, 24, 36, 48, 60, 72, 84, 96 and 104 (Study 112)
|
The CFQ-R is a validated participant reported outcome measuring health related quality of life for participants with CF.
Respiratory domain assessed respiratory symptoms (for example, coughing, congestion, wheezing), score range: 0-100; higher scores indicating fewer symptoms and better health related quality of life.
Baseline was defined as the most recent measurement before intake of the first dose of study drug (ivacaftor) in Study 112.
Results were planned to be reported for Ivacaftor arm and were stratified by parent study 110, 111 and 113.
|
Baseline, Week 2, 12, 24, 36, 48, 60, 72, 84, 96 and 104 (Study 112)
|
Number of Pulmonary Exacerbations Events
Time Frame: Through Week 104 (Study 112)
|
Pulmonary exacerbation events include those events which require treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms.
The number of events were reported.
Results were planned to be reported for Ivacaftor arm and were stratified by parent study 110, 111 and 113.
|
Through Week 104 (Study 112)
|
Number of Participants With Serious Adverse Events (SAEs) in Observational Arm
Time Frame: up to 2 years (Study 112)
|
SAE was defined as a medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, In-patient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event.
|
up to 2 years (Study 112)
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Joseph Pilewski, MD, University of Pittsburgh
Publications and helpful links
General Publications
- Moss RB, Flume PA, Elborn JS, Cooke J, Rowe SM, McColley SA, Rubenstein RC, Higgins M; VX11-770-110 (KONDUCT) Study Group. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial. Lancet Respir Med. 2015 Jul;3(7):524-33. doi: 10.1016/S2213-2600(15)00201-5. Epub 2015 Jun 9.
- Pilewski JM, De Boeck K, Nick JA, Tian S, DeSouza C, Higgins M, Moss RB. Long-Term Ivacaftor in People Aged 6 Years and Older with Cystic Fibrosis with Ivacaftor-Responsive Mutations. Pulm Ther. 2020 Dec;6(2):303-313. doi: 10.1007/s41030-020-00129-2. Epub 2020 Sep 23.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- VX12-770-112
- 2012-000389-39 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cystic Fibrosis
-
Hospital de Clinicas de Porto AlegreUnknownCystic Fibrosis | Cystic Fibrosis Pulmonary Exacerbation | Cystic Fibrosis in Children | Cystic Fibrosis With ExacerbationBrazil
-
University of Colorado, DenverCystic Fibrosis FoundationTerminatedCystic Fibrosis-related Diabetes | Cystic Fibrosis Pulmonary Exacerbation | Cystic Fibrosis in ChildrenUnited States
-
Royal College of Surgeons, IrelandThe Hospital for Sick Children; Imperial College London; Erasmus Medical Center; University College Dublin and other collaboratorsActive, not recruitingCystic Fibrosis | Adherence, Medication | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis in Children | Cystic Fibrosis Liver DiseaseUnited Kingdom, Ireland
-
Herlev and Gentofte HospitalCopenhagen University Hospital, DenmarkActive, not recruitingMyocardial Infarction | Heart Diseases | Heart Failure | Stroke | Cystic Fibrosis | Heart Failure, Diastolic | Heart Failure, Systolic | Left Ventricular Dysfunction | Cystic Fibrosis-related Diabetes | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis of Pancreas | Cystic Fibrosis, Pulmonary | Cystic...Denmark
-
The Hospital for Sick ChildrenCanadian Cystic Fibrosis FoundationActive, not recruitingCystic Fibrosis | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis in ChildrenCanada
-
Arrowhead PharmaceuticalsTerminatedCystic Fibrosis, PulmonaryAustralia, New Zealand
-
AzurRx SASCompletedCystic Fibrosis | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis of PancreasTurkey, Hungary
-
Dartmouth-Hitchcock Medical CenterTrustees of Dartmouth CollegeWithdrawnCystic Fibrosis-related Diabetes | Cystic Fibrosis Liver Disease | CF - Cystic FibrosisUnited States
-
University Hospital, BordeauxCompleted
-
University of PortsmouthUniversity Hospital Southampton NHS Foundation Trust; Loughborough University; Queen Alexandra HospitalTerminated
Clinical Trials on Ivacaftor
-
Vertex Pharmaceuticals IncorporatedCompleted
-
Charite University, Berlin, GermanyHannover Medical School; Heidelberg University; University of GiessenRecruiting
-
Vertex Pharmaceuticals IncorporatedCompletedCystic FibrosisUnited States, United Kingdom, Germany, Spain, Switzerland, Canada, Netherlands, Italy, Ireland, Sweden, France, Denmark
-
Vertex Pharmaceuticals IncorporatedCompletedCystic FibrosisUnited States, Australia, Canada, Germany, Switzerland, Israel, Netherlands, Belgium, Italy, United Kingdom, France
-
Vertex Pharmaceuticals IncorporatedCompletedCystic FibrosisUnited States, Canada, France, Spain, Israel, Australia, Austria
-
The AlfredUnknown
-
Vertex Pharmaceuticals IncorporatedCystic Fibrosis FoundationCompletedCystic FibrosisUnited States, Canada, Germany
-
Vertex Pharmaceuticals IncorporatedCompletedCystic FibrosisUnited States, Germany, United Kingdom, Canada, Australia, Switzerland, France, Ireland, Belgium, Denmark, Poland
-
Vertex Pharmaceuticals IncorporatedCompletedCystic FibrosisUnited States, Australia, Canada, France, United Kingdom, Germany, Spain, Switzerland, Belgium, Israel, Netherlands, Denmark, Italy, Austria, Ireland, Sweden
-
Vertex Pharmaceuticals IncorporatedCompletedCystic FibrosisBelgium, United Kingdom, Australia, Germany